- Home
- HIFS vs KROS Comparison
HIFS vs KROS Comparison
Compare HIFS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- KROS
- Stock Information
- Founded
- HIFS 1834
- KROS 2015
- Country
- HIFS United States
- KROS United States
- Employees
- HIFS N/A
- KROS N/A
- Industry
- HIFS Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- HIFS Finance
- KROS Health Care
- Exchange
- HIFS Nasdaq
- KROS Nasdaq
- Market Cap
- HIFS 611.4M
- KROS 565.0M
- IPO Year
- HIFS N/A
- KROS 2020
- Fundamental
- Price
- HIFS $277.68
- KROS $15.56
- Analyst Decision
- HIFS
- KROS Buy
- Analyst Count
- HIFS 0
- KROS 14
- Target Price
- HIFS N/A
- KROS $20.56
- AVG Volume (30 Days)
- HIFS 44.4K
- KROS 474.1K
- Earning Date
- HIFS 10-10-2025
- KROS 08-06-2025
- Dividend Yield
- HIFS 0.91%
- KROS N/A
- EPS Growth
- HIFS 63.41
- KROS N/A
- EPS
- HIFS 15.35
- KROS 0.47
- Revenue
- HIFS $75,066,000.00
- KROS $232,844,000.00
- Revenue This Year
- HIFS N/A
- KROS $5,579.44
- Revenue Next Year
- HIFS N/A
- KROS N/A
- P/E Ratio
- HIFS $17.19
- KROS $32.60
- Revenue Growth
- HIFS 37.00
- KROS 85820.30
- 52 Week Low
- HIFS $209.71
- KROS $9.12
- 52 Week High
- HIFS $300.00
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- HIFS 68.47
- KROS 66.70
- Support Level
- HIFS $252.28
- KROS $14.04
- Resistance Level
- HIFS $264.90
- KROS $15.39
- Average True Range (ATR)
- HIFS 7.77
- KROS 0.60
- MACD
- HIFS 2.74
- KROS 0.13
- Stochastic Oscillator
- HIFS 96.91
- KROS 90.68
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.